This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Allergies Remove Dermatology Remove Gene Editing Related Topics
Botox Generic Pharmaceutical Bacterium Big Data Generic Drugs Cosmetics Containment In-Vitro Licensing Insulin More Related Topics >
article thumbnail

Clinical Catch-Up: January 18-22 | BioSpace

The Pharma Data

JANUARY 24, 2021

It inked a deal with the National Institute of Allergy and Infectious Diseases (NIAID) to launch a Phase I trial. National Institute of Allergy and Infectious Diseases (NIAID), of bamlanivimab (LY-CoV555) decreased the risk of COVID-19 among residents and staff of long-term care facilities, i.e., nursing homes.

Trials 52
Trials Allergies In-Vitro Antibody 52
article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

AUGUST 2, 2023

It also has a significant presence in consumer health sectors such as dermatology, nutritionals and allergy. This growth was propelled by the expansion of its development portfolio in cell and gene therapies, as well as advancements in late-stage pharmaceutical pipeline drugs like asundexian and elinzanetant.

Sales 98
Sales Manufacturing FDA Approval Life Science 98
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 32,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024